2'-Deoxy-2',2'-difluoro-D-cytidine-5'-O-[phenyl-(cyclohexoxy-L-alaninyl)]-phosphate

ID: ALA3126003

Chembl Id: CHEMBL3126003

PubChem CID: 76332707

Max Phase: Preclinical

Molecular Formula: C24H31F2N4O8P

Molecular Weight: 572.50

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@H](NP(=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OC1CCCCC1

Standard InChI:  InChI=1S/C24H31F2N4O8P/c1-15(21(32)36-16-8-4-2-5-9-16)29-39(34,38-17-10-6-3-7-11-17)35-14-18-20(31)24(25,26)22(37-18)30-13-12-19(27)28-23(30)33/h3,6-7,10-13,15-16,18,20,22,31H,2,4-5,8-9,14H2,1H3,(H,29,34)(H2,27,28,33)/t15-,18+,20+,22+,39?/m0/s1

Standard InChI Key:  LVHYUTBYVPPDHJ-VKTBRLFESA-N

Associated Targets(Human)

CCRF-CEM (65223 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MIA PaCa-2 (5949 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
BXPC-3 (2997 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hepatocyte (2737 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver microsome (8277 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MM1.S (1111 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

L1210 (27553 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 572.50Molecular Weight (Monoisotopic): 572.1848AlogP: 2.78#Rotatable Bonds: 10
Polar Surface Area: 164.23Molecular Species: NEUTRALHBA: 11HBD: 3
#RO5 Violations: 2HBA (Lipinski): 12HBD (Lipinski): 4#RO5 Violations (Lipinski): 2
CX Acidic pKa: 10.22CX Basic pKa: CX LogP: 2.09CX LogD: 2.09
Aromatic Rings: 2Heavy Atoms: 39QED Weighted: 0.28Np Likeness Score: 0.53

References

1. Slusarczyk M, Lopez MH, Balzarini J, Mason M, Jiang WG, Blagden S, Thompson E, Ghazaly E, McGuigan C..  (2014)  Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.,  57  (4): [PMID:24471998] [10.1021/jm401853a]
2. Zhang L, Qi K, Xu J, Xing Y, Wang X, Tong L, He Z, Xu W, Li X, Jiang Y..  (2023)  Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine.,  66  (6): [PMID:36867101] [10.1021/acs.jmedchem.3c00006]

Source